Abstract
Reactions of 5-(1,3-benzothiazol-2-yl)furan-2-carbaldehyde with 2-acetylfuran, 2-acetylthiophene, and some compounds containing an active methylene group gave a number of new 3-[5-(1,3-benzothiazol-2-yl)furan-2-yl]-1-(furan- or thiophen-2-yl)prop-2-en-1-one, 3-[5-(1,3-benzothiazol-2-yl)furan-2-yl]acrylonitrile, 3-[5-(1,3-benzothiazol-2-yl)furan-2-yl]-2-cyanoacrylamide, and 5-{[5-(1,3-benzothiazol-2-yl)furan-2-yl]methylidene}-2-sulfanylidene-1,3-thiazolidin-4-one derivatives. 5-{[5-(1,3-Benzothiazol-2-yl)furan-2-yl]methylidene}-2-(morpholin-4-yl)-1,3-thiazol-4-one and diethyl 4-[5-(1,3-benzothiazol-2-yl)furan-2-yl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate were synthesized by multicomponent reactions involving the title compound. Antitumor screening of the synthesized 5-(1,3-benzothiazol-2-yl)furan-2-carbaldehyde derivatives revealed a lead compound, 3-[5-(1,3-benzothiazol-2-yl)furan-2-yl]-2-(4-phenyl-1,3-thiazol-2-yl)prop-2-enenitrile, which proved to be superior to 5-fluorouracil, cisplatin, and curcumin taken as reference drugs.
Similar content being viewed by others
REFERENCES
Tariq, S., Kamboj, P., and Amir, M., Arch. Pharm., 2018, vol. 352, article ID e1800170. https://doi.org/10.1002/ardp.201800170
Irfan, A., Batool, F., Zahra Naqvi, S.A., Islam, A., Osman, S.M., Nocentini, A., Alissa, S.A., and Supuran, C.T., J. Enzyme Inhib. Med. Chem., 2020, vol. 35, p. 265. https://doi.org/10.1080/14756366.2019.1698036
Gao, X., Liu, J., Zuo, X., Feng, X., and Gao, Y., Molecules, 2020, vol. 25, p. 1675. https://doi.org/10.3390/molecules25071675.
Jain, S., Pattnaik, S., Pathak, K., Kumar, S., Pathak, D., Jain, S., and Vaidya, A., Mini Rev. Med. Chem., 2018, vol. 18, p. 640. https://doi.org/10.2174/1389557517666171123211321
Pathak, N., Rathi, E., Kumar, N., Kini, S.G., and Rao, C.M., Mini Rev. Med. Chem., 2020, vol. 20, p. 12. https://doi.org/10.2174/1389557519666190617153213
Eshkil, F., Eshghi, H., Saljooghi, A.S., Bakavoli, M., and Rahimizadeh, M., Russ. J. Bioorg. Chem., 2017, vol. 43, p. 576. https://doi.org/10.1134/S1068162017050065
Singh, M., Modi, A., Narayan, G., and Singh, S.K., Anticancer Drugs, 2016, vol. 27, p. 519. https://doi.org/10.1097/CAD.0000000000000357
Hutchinson, I., Jennings, S.A., Vishnuvajjala, B.R., Westwell, A.D., and Stevens, M.F., J. Med. Chem., 2002, vol. 45, p. 744. https://doi.org/10.1021/jm011025r
Horishny, V., Kartsev, V., Geronikaki, A., Matiychuk, V., Petrou, A., Glamoclija, J., Ciric, A., and Sokovic, M., Molecules, 2020, vol. 25, p. 1964. https://doi.org/10.3390/molecules25081964
Obushak, N.D., Gorak, Yu.I., Matiichuk, V.S., and Lytvyn, R.Z., Russ. J. Org. Chem., 2008, vol. 44, p. 1689. https://doi.org/10.1134/S1070428008110213
Pokhodylo, N.T., Matiychuk, V.S., and Obushak, N.D., Chem. Heterocycl. Compd., 2009, vol. 45, p. 483. https://doi.org/10.1007/s10593-009-0287-6
Tsyalkovsky, V.M., Kutsyk, R.V., Matiychuk, V.S., Obushak, N.D., and Klyufinskaya, T.I., Pharm. Chem. J., 2005, vol. 39, p. 245. https://doi.org/10.1007/s11094-005-0126-8
Pokhodylo, N.T. and Matiychuk, V.S., J. Heterocycl. Chem., 2010, vol. 47, p. 415. https://doi.org/10.1002/jhet.321
Pokhodylo, N.T., Matiychuk, V.S., and Obushak, M.D., Synthesis, 2009, vol. 2009, no. 8, p. 1297. https://doi.org/10.1055/s-0028-1087992
Pokhodylo, N.T., Teslenko, Y.O., Matiychuk, V.S., and Obushak, M.D., Synthesis, 2009, vol. 2009, no. 16, p. 2741. https://doi.org/10.1055/s-0029-1216875
Pokhodylo, N.T., Matiychuk, V.S., and Obushak, N.D., Chem. Heterocycl. Compd., 2009, vol. 45, p. 121. https://doi.org/10.1007/s10593-009-0238-2
Obushak, M.D., Matiychuk, V.S., and Lytvyn, R.Z., Chem. Heterocycl. Compd., 2008, vol. 44, p. 936. https://doi.org/10.1007/s10593-008-0135-0
Chaban, T.I., Ogurtsov, V.V., Matiychuk, V.S., Chaban, I.G., Demchuk, I.L., and Nektegayev, I.A., Acta Chim. Slov., 2019, vol. 66, p. 103. https://doi.org/10.17344/acsi.2018.4570
Obushak, M.D., Matiychuk, V.S., and Turytsya, V.V., Tetrahedron Lett., 2009, vol. 50, p. 6112. https://doi.org/10.1016/j.tetlet.2009.08.024
Pokhodylo, N.T., Shyyka, O.Y., Matiychuk, V.S., and Obushak, M.D., ACS Comb. Sci., 2015, vol. 17, p. 399. https://doi.org/10.1021/co5001376
Tymoshuk, O.S., Fedyshyn, O.S., Oleksiv, L.V., Rydchuk, P.V., and Matiychuk, V.S., J. Chem., 2020, vol. 2020, article ID 8141853. https://doi.org/10.1155/2020/8141853
Bazel, Y., Tupys, A., Ostapiuk, Y., Tymoshuk, O., and Matiychuk, V., J. Mol. Liq., 2017, vol. 242, p. 471. https://doi.org/10.1016/j.molliq.2017.07.047
Tupys, A., Kalembkiewicz, J., Ostapiuk, Y., Matiichuk, V., Tymoshuk, O., Woźnicka, E., and Byczyński, Ł., J. Therm. Anal. Calorim., 2017, vol. 127, p. 2233. https://doi.org/10.1007/s10973-016-5784-0
Lozyns’ka, L.V., Tymoshuk, O.S., and Vrublevs’ka, T.Y., Mater. Sci., 2015, vol. 50, p. 870. https://doi.org/10.1007/s11003-015-9795-y
Lozynska, L. and Tymoshuk, O., Chem. Chem. Technol., 2013, vol. 7, p. 391. https://doi.org/10.23939/chcht07.04.391
Tupys, A., Tymoshuk, O., and Rydchuk, P., Chem. Chem. Technol., 2016, vol. 10, p. 19. https://doi.org/10.23939/chcht10.01.019
Paizs, C., Toșa, M.I., Majdik, C., Taehtinen, P., Irimie, F.D., and Kanerva, L.T., Tetrahedron: Asymmetry, 2003, vol. 14, p. 619. https://doi.org/10.1016/S0957-4166(03)00025-9
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M., J. Natl. Cancer Inst., 1991, vol. 83, p. 757. https://doi.org/10.1093/jnci/83.11.757
Boyd, M.R. and Paull, K.D., Drug Dev. Res., 1995, vol. 34, p. 91. https://doi.org/10.1002/ddr.430340203
Boyd, M.R., Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Teicher, B.A., Ed., Totowa: Humana Press, 1997, p. 23.
Shoemaker, R.H., Nat. Rev. Cancer, 2006, vol. 6, p. 813. https://doi.org/10.1038/nrc1951
Rostom, S.A., Bioorg. Med. Chem., 2006. vol. 14, p. 6475. https://doi.org/10.1016/j.bmc.2006.06.020
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare the absence of conflict of interest.
Rights and permissions
About this article
Cite this article
Matiichuk, Y.E., Horak, Y.I., Chaban, T.I. et al. 5-(1,3-Benzothiazol-2-yl)furan-2-carbaldehyde in the Design of Antitumor Agents. Russ J Org Chem 56, 1720–1727 (2020). https://doi.org/10.1134/S1070428020100085
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1070428020100085